A text version of the Hyperglycaemia - Initial Assessment flowchart is also available.
[1. d'Emden MC, Shaw JE, Colman PG, Colagiuri S, Twigg SM, Jones GR, et al. The role of HbA1c in the diagnosis of diabetes mellitus in Australia. Med J Aust 2012;197:220-1.]
HbA1c levels have been validated in the diagnosis of diabetes. They have not been adequately validated in the estimation of cardiovascular disease risk, and cannot determine IFG and IGT, where elevated CVD risk also needs to be considered.
For this reason, GTT remains the risk stratification tool where there is non-diabetic hyperglycaemia.
[Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Dia Care. 1999 May 1;22(5):696-9.]
If you find any errors or omissions in these Guidelines, or feel that something in them needs to change, write to:
DameClinGuide.feedback@casa.gov.au
Please include details of the page on which you wish to provide feedback.
Thank you for your assistance in ensuring that these Guidelines are up to date and correct.
The Clinical Practice Guideline is provided by way of guidance only and subject to the Clinical practice guidelines disclaimer